METHODS OF TREATING ACUTE MYELOID LEUKEMIA WITH A FLT3 MUTATION
There is provided a method of treating acute myeloid leukemia (AML). The method includes the step of administering to a patient having AML with a FMS-like tyrosine kinase 3 (FLT3)-mutation a therapeutically effective amount of a CXCR4-antagonistic peptide.
1 . A method of treating acute myeloid leukemia (AML), the method comprising administrating to a subject having AML with a FMS-like tyrosine kinase 3 (FLT3) mutation a therapeutically effective amount of a CXCR4-antagonistic peptide, thereby treating the AML.
2 . A method of treating acute myeloid leukemia (AML), the method comprising the steps of:
(a) identifying a subject having AML with a FMS-like tyrosine kinase 3 (FLT3) mutation; and
(b) administrating to said subject a therapeutically effective amount of a CXCR4-antagonistic peptide, thereby treating the AML with a FLT3 mutation.
3 - 4 . (canceled)
5 . An article of manufacture identified for the treatment of AML with a FMS-like tyrosine kinase 3 (FLT3) mutation comprising a CXCR4-antagonistic peptide and a chemotherapeutic agent.
6 . The article of manufacture of claim 5 , wherein said CXCR4-antagonistic peptide and said chemotherapeutic agent are in separate containers.
7 . The method of claim 1 , wherein said FLT3 mutation is a FLT3 internal tandem duplication (ITD) mutation.
8 . The method of claim 1 , wherein said CXCR4-antagonistic peptide is as set forth in SEQ ID NO: 1.
9 . The method of claim 1 , wherein said CXCR4-antagonistic peptide is administered to said subject in a daily amount between 0.1 to 10 mg per kg of body weight.
10 . The method of claim 1 , wherein said CXCR4-antagonistic peptide is administered subcutaneously.
11 . The method of claim 1 , wherein said CXCR4-antagonistic peptide is administered intravenously.
12 . The method of claim 1 further comprising a step of administering to said subject a therapeutically effective amount of a chemotherapeutic agent.
13 . The method of claim 12 , wherein said chemotherapeutic agent is cytarabine (ARA-C).
14 . The method of claim 12 , wherein said chemotherapeutic agent is quizartinib (AC220).
15 . The method of claim 12 , wherein said chemotherapeutic agent synergizes with said CXCR4-antagonistic peptide in inducing apoptosis of AML cells.
16 . The method of claim 1 , for reducing minimal residual disease of AML cells.
17 . The method claim 2 , wherein said FLT3 mutation is a FLT3 internal tandem duplication (ITD) mutation.
18 . The method of claim 2 , wherein said CXCR4-antagonistic peptide is as set forth in SEQ ID NO: 1.
19 . The method of claim 2 , further comprising a step of administering to said subject a therapeutically effective amount of a chemotherapeutic agent.
20 . The method of claim 19 , wherein said chemotherapeutic agent is cytarabine (ARA-C).
21 . The method of claim 19 , wherein said chemotherapeutic agent is quizartinib (AC220).
22 . The method of claim 19 , wherein said chemotherapeutic agent synergizes with said CXCR4-antagonistic peptide in inducing apoptosis of AML cells.
23 . The method of claim 2 , for reducing minimal residual disease of AML cells.